Geode Capital Management
OPNT

Geode Capital Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Geode Capital Management’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-48,591
Closed -$985K – 4889
2022
Q4 		$985K Sell
48,591
-136
-0.3% -$2.08K ﹤0.01% 3343
2022
Q3 		$523K Buy
48,727
+167
+0.3% +$1.89K ﹤0.01% 3704
2022
Q2 		$582K Buy
48,560
+562
+1% +$9.06K ﹤0.01% 3682
2022
Q1 		$1.03M Sell
47,998
-2,246
-4% -$59.5K ﹤0.01% 3612
2021
Q4 		$1.69M Hold
50,244
– – ﹤0.01% 3457
2021
Q3 		$1.29M Buy
50,244
+37,362
+290% +$668K ﹤0.01% 3555
2021
Q2 		$178K Hold
12,882
– – ﹤0.01% 4382
2021
Q1 		$136K Buy
+12,882
New +$147K ﹤0.01% 4227

Geode Capital Management's OPNT Position: Q1 2023 in Review

Geode Capital Management sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 48,591 shares — an estimated $985K sold.

Geode Capital Management first reported a position in OPNT in Q1 2021 and held it in 8 quarters. The position peaked at $1.69M in Q4 2021. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

  • Geode Capital Management reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Geode Capital Management sold 48,591 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $985K.
  • Geode Capital Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Geode Capital Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $1.69M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Geode Capital Management's 13F filing for Q1 2023, filed 15 May 2023.